WeWork's newest Houston-area location is headed to The Woodlands. Courtesy of WeWork

In 2018, WeWork more than doubled its presence in Houston in terms of desks available. The company went from one location in the Galleria area with 1,100 desks to adding a second location in downtown with 1,500 desks. In 2019, WeWork is expected to again double the number of coworking desks the company will have by the end of the year — most new desk space will come from WeWork's new location in The Woodlands.

"In 2018, WeWork grew its footprint in a very big way in Houston. Now, in 2019, we're growing even more, but in a way that's as much about desks as it is impact," says Roniel Bencosme, WeWork Houston's community director, in a news release. "In this next year, WeWork will build a constellation of opportunity through new spaces spread across Houston, and opening in the Woodlands is key to that effort."

WeWork will have 1,000 desks at the new northwest location (1725 Hughes Landing) across two floors and 52,000 square feet of space, according to the release. WeWork Galleria will add 775 desks in the fourth quarter of 2019, and 1,000 more desks will be added by end of the year pending new leases, the release says. Regionally, WeWork has a presence in five cities in Texas — Dallas, Fort Worth, Houston, Austin, and Plano — but will launch in its sixth Texas city, San Antonio, in early 2020.

In 2019, WeWork will also be growing its social impact programs on a national level in addition to its footprint. Recently, WeWork formed a partnership with the Female Founders Alliance, the Tent Partnership for Refugees, to hire 1,500 refugees at WeWork over the next five years. The company's veterans hiring initiative will also be hiring 1,500 veterans over the next five years.

Houstonians can also expect to see new WeWork Labs, WeWork's accelerator concept, around town, as well as the Veterans in Residence third cohort. WeWork's Flatiron School, which is in its downtown Houston location, will see new cohorts and boasts of a 98 percent job rate placement rate. The school alsy awarded $200,000 in scholarship dollars last year.

"Impact for WeWork is about enabling opportunity. We unlock access to thriving workspaces for companies of all sizes that would otherwise be out of reach," Bencosme says in the release. "We help cities like Houston attract top companies and reduce friction for them to put down roots. We're creating synergies and connectivity across the metro region at a level and scale that's never been done before. That's impact.

WeWork recently released its Global Impact Report for 2019, and the research tracked specifics about its Houston membership. Here were some key findings of the study locally:

  • The majority of Houston WeWork members (83 percent) are in the innovation economy, compared to 12% in the region as a whole.
  • When it comes to sustainable commuting, 42 percent of WeWork members walk, bike, or use public transit to go to work.
  • The Houston WeWork economy contributes over $1 billion to the city's GDP — either directly ($480 million) or indirectly ($530 million)
  • WeWork's small and medium-sized member companies in Houston have an average job growth rate of 32 percent (compared to 1 percent for all companies in Houston).
  • In Houston, 58 percent of WeWork members say the organization has helped their company accelerate its growth.
  • While 44 percent of senior roles at U.S. WeWork member companies are held by women, Houston's percentage of female-led companies at WeWork locally is slightly lower at 36 percent.
  • Of WeWork members that are entrepreneurs in Houston, 26 percent are first-time entrepreneurs, and 1 in 20 of the city's first-time entrepreneurs are WeWork members.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”